Biocon launches diabetes, obesity management drug in UK

Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide. This follows approval from the UK's MHRA, making Biocon the first generics company to gain such approval in a major regulated market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vB1bDCs
via IFTTT